Aditxt Inc Stock Price, News & Analysis

Aditxt (NASDAQ: ADTX) announced that Appili Therapeutics (TSX: APLI; OTCPink: APLIF) will hold a special meeting on November 6, 2024, for shareholders to vote on Aditxt's proposed acquisition. Appili's board recommends voting in favor. Appili has raised CAD $100M for developing infectious disease and biodefense therapeutics. Its portfolio includes:

1. LIKMEZ™: FDA-approved liquid antibiotic

2. ATI-1701: Tularemia vaccine with $14M in funding

3. ATI-1801: Topical treatment for cutaneous leishmaniasis

Two programs may be eligible for FDA Priority Review Vouchers. The acquisition aims to expand Aditxt's reach in addressing infectious diseases and public health challenges.

Aditxt (NASDAQ: ADTX) has announced a stakeholder update and Q&A session scheduled for Friday, October 11, 2024, at 11:30 AM EDT. CEO Amro Albanna will lead the session, covering:

• Company overview and updates on Evofem and Appili transactions
• Current programs in immune and precision health
• Year-end roadmap for 2024
• Q&A segment addressing pre-submitted questions

Aditxt operates two programs focused on immune health and precision health, with plans to introduce two additional programs in public health and women's health. The company has entered into agreements with Appili Therapeutics and Evofem Biosciences for these new programs. Aditxt's innovation platform aims to accelerate promising health innovations through collaboration with research institutions, industry partners, and shareholders.

Aditxt (NASDAQ: ADTX) has completed the Third Parent Equity Investment in Evofem Biosciences (OTCQB: EVFM) under their Amended and Restated Merger Agreement. Aditxt purchased 460 shares of Evofem Series F-1 Convertible Preferred Stock for $460,000, bringing their total investment to $1.72 million. Aditxt plans to complete the Fourth Parent Equity Investment of $2.28 million by October 31, 2024.

Evofem has expanded from a single-product company to offering diversified solutions in women's health, including Phexxi (contraceptive gel) and SOLOSEC (antibiotic). They are preparing to launch the Mitomic Endometriosis Test in mid-2025 and have signed a licensing agreement with Pharma 1 Drug Store to bring Phexxi to the Gulf Cooperation Council region.

Aditxt aims to accelerate innovative health companies through its business platform, which includes subsidiaries Adimune (immune health) and Pearsanta (precision health). Both companies believe the merger will strengthen Evofem's ability to expand access to women's health products globally.

Aditxt, Inc. (NASDAQ: ADTX) has announced a 1-for-40 reverse stock split effective at the open of trading on October 2, 2024. The company's common stock will continue to trade under the symbol ADTX on the Nasdaq Capital Market. This decision was approved by stockholders on August 7, 2024, with the final ratio determined by the board of directors.

Key points:

• New CUSIP number: 007025703
• Every 40 shares will be exchanged for 1 share
• Fractional shares will be rounded up
• Post-split: approximately 244,667 shares outstanding

The primary goal of this reverse split is to bring Aditxt into compliance with Nasdaq's minimum bid price requirement. More information can be found in the company's definitive proxy statement filed on July 5, 2024.

Aditxt, Inc. (NASDAQ: ADTX) announced that its acquisition target, Evofem Biosciences, Inc. (OTCQB: EVFM), has filed a preliminary proxy to seek stockholder approval for the merger outlined in the Amended and Restated Merger Agreement dated July 12, 2024. The agreement involves Adifem, Inc., a wholly-owned subsidiary of Aditxt, merging with Evofem, resulting in Evofem becoming a wholly-owned subsidiary of Aditxt.

The companies are targeting to close the transaction in the fourth quarter of 2024, subject to Evofem stockholder approval and other closing conditions, including Aditxt raising sufficient capital to fund its obligations at closing. However, no assurance is provided that all conditions will be met or that the transaction will ultimately close.

Aditxt, Inc. (NASDAQ: ADTX) announced that its subsidiary, Pearsanta, has entered into a collaboration agreement with Evofem Biosciences for the U.S. launch of a blood-based diagnostic test for endometriosis in mid-2025. The Mitomic® Endometriosis Test (MET™) detects a specific deletion in mitochondrial DNA, a novel biomarker for endometriosis.

Endometriosis affects approximately 190 million women worldwide, with no current validated blood-based tests available. The collaboration aims to develop a go-to-market strategy and commercial plan for MET. Over 300 endometriosis cases have been evaluated using MET, with 600 planned for clinical validation.

This partnership aligns with Evofem's strategy to expand its women's health product offerings and Aditxt's goal of accelerating healthcare innovations. The collaboration may also lead to future tests, such as early detection of ovarian cancer.

Aditxt (NASDAQ: ADTX) and Evofem Biosciences (OTCQB: EVFM) have signed a Second Amendment to their merger agreement, extending the timeline for Aditxt's $3 million funding to Evofem. The acquisition is now targeted to close in Q4 2024. Evofem aims to grow revenue through its three-pronged strategy: increasing U.S. sales of Phexxi® and SOLOSEC®, expanding its portfolio, and pursuing international partnerships. Aditxt plans to introduce four health-focused programs, including women's health through the Evofem merger. The deal's completion depends on shareholder approvals and Aditxt securing sufficient capital.

Aditxt (NASDAQ: ADTX) subsidiary Pearsanta has submitted a $2 million grant application to the DoD's Prostate Cancer Research Program. The funding aims to advance clinical trials for the Mitomic® Prostate Test (MPT™), a blood test for early detection of clinically significant prostate cancer. The proposed study involves validating MPT™ and conducting a randomized clinical trial with up to 1,000 men to evaluate its effectiveness in reducing unnecessary biopsies.

The prostate cancer diagnostic market is expected to grow from $6.2 billion in 2023 to $11.5 billion by 2032. Prostate cancer affects 1 in 8 men, with an estimated 299,010 new cases and 35,250 deaths expected in the US this year. Pearsanta's Mitomic Technology Platform uses mitochondrial DNA mutations for early disease detection, focusing on various cancers and conditions like endometriosis.

Aditxt Inc. (NASDAQ: ADTX) announced the appointment of Christopher Mitton as President of its subsidiary, Pearsanta Inc. Mitton brings over 20 years of leadership experience in medical diagnostics, focusing on personalized healthcare and molecular oncology. Pearsanta specializes in developing diagnostic tests for cancer, cardiology, immunology, gut health, and chronic conditions using proprietary platforms like Mitomic® Technology and AditxtScore™.

Under Mitton's leadership, Pearsanta aims to complete clinical validation studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™), with plans for commercial launch as laboratory developed tests. The company is also finalizing validation for the Mitomic® Ovarian Test (MOT™). Pearsanta's strategy includes leveraging existing partnerships and internal synergies within Aditxt to drive revenue and accelerate test adoption globally.